| Literature DB >> 22328999 |
Elvira Vaclavik Bräuner1, Mette Sørensen, Eric Gaudreau, Alain LeBlanc, Kirsten Thorup Eriksen, Anne Tjønneland, Kim Overvad, Ole Raaschou-Nielsen.
Abstract
BACKGROUND: Exposure to organochlorines has been examined as a potential risk factor for non-Hodgkin lymphoma (NHL), with inconsistent results that may be related to limited statistical power or to imprecise exposure measurements.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22328999 PMCID: PMC3261942 DOI: 10.1289/ehp.1103573
Source DB: PubMed Journal: Environ Health Perspect ISSN: 0091-6765 Impact factor: 9.031
Organochlorines in adipose tissue from case and subcohort members.
| IQR (all; μg/kg lipid) | Above LOD [ | Median (5th–95th percentile; μg/kg lipid) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Compound | Cases | Subcohort | Cases | Subcohort | ||||||
| 21 | 137 (57.3) | 137 (55.9) | 24 (9–83) | 21 (10–58) | ||||||
| 710 | 238 (99.6) | 237 (96.7) | 700 (180–2,400) | 640 (170–2,300) | ||||||
| β-Hexachlorocyclohexane | 32 | 225 (94.1) | 220 (89.8) | 59 (31–110) | 56 (33–115) | |||||
| 4.7 | 155 (64.9) | 156 (63.7) | 8.1 (3.5–17.0) | 6.8 (3.1–16.0) | ||||||
| 21 | 235 (98.3) | 232 (94.7) | 35 (17–76) | 32 (16–71) | ||||||
| Oxychlordane | 14 | 169 (70.7) | 171 (69.8) | 26 (15–47) | 23 (12–45) | |||||
| Dieldrin | 16 | 140 (58.6) | 144 (59.0) | 24 (9–49) | 18 (8–49) | |||||
| Hexachlorobenzene | 35 | 204 (85.4) | 213 (86.9) | 54 (20–120) | 52 (19–110) | |||||
| PCB-118 | 23 | 233 (97.5) | 233 (95.1) | 34 (16–70) | 35 (17–72) | |||||
| PCB-156 | 13 | 235 (98.3) | 236 (96.3) | 34 (20–61) | 34 (21–57) | |||||
| PCB-99 | 16.5 | 171 (71.5) | 177 (72.2) | 28 (14–57) | 26 (12–53) | |||||
| PCB-138 | 80 | 238 (99.6) | 243 (99.2) | 150 (57–270) | 140 (66–260) | |||||
| PCB-153 | 130 | 239 (100.0) | 244 (99.6) | 300 (170–470) | 300 (160–510) | |||||
| PCB-170 | 43 | 238 (99.6) | 243 (99.2) | 100 (65–170) | 100 (68–170) | |||||
| PCB-180 | 70 | 239 (100.0) | 245 (100.0) | 200 (120–340) | 200 (130–320) | |||||
| PCB-183 | 12 | 226 (94.6) | 227 (92.7) | 25 (11–40) | 24 (12–47) | |||||
| PCB-187 | 22 | 238 (99.6) | 240 (98.0) | 58 (29–92) | 56 (30–99) | |||||
| PCB-201 | 8 | 224 (93.7) | 227 (92.7) | 19 (11–33) | 19 (11–31) | |||||
IRRs of NHL in association with adipose tissue concentrations of organochlorine pesticides.
| Compound/concentration | IRR (95% CI) | |||||
|---|---|---|---|---|---|---|
| Model 1 | Model 2 | |||||
| 6–15 | 29/37 | 1.00 | 1.00 | |||
| 15–22 | 32/32 | 1.09 (0.54, 2.18) | 1.06 (0.52, 2.14) | |||
| 22–36 | 35/38 | 1.12 (0.57, 2.19) | 1.03 (0.51, 2.09) | |||
| 36–49 | 23/19 | 1.25 (0.55, 2.80) | 1.21 (0.53, 2.75) | |||
| 49–460 | 18/11 | 1.73 (0.72, 4.14) | 1.64 (0.68, 3.96) | |||
| Linear estimate per IQR | 137/137 | 1.36 (1.11, 1.68) | 1.35 (1.10, 1.66) | |||
| 68–390 | 59/58 | 1.00 | 1.00 | |||
| 390–680 | 53/64 | 0.82 (0.49, 1.37) | 0.83 (0.49, 1.39) | |||
| 680–1,100 | 63/57 | 1.03 (0.62, 1.72) | 1.04 (0.62, 1.73) | |||
| 1,100–1,700 | 34/36 | 0.82 (0.45, 1.50) | 0.79 (0.43, 1.46) | |||
| 1,700–8,000 | 29/22 | 1.12 (0.58, 2.17) | 1.10 (0.57, 2.14) | |||
| Linear estimate per IQR | 238/237 | 1.03 (0.86, 1.22) | 1.02 (0.86, 1.22) | |||
| β-Hexachlorocyclohexane | ||||||
| 15–45 | 50/60 | 1.00 | 1.00 | |||
| 45–57 | 50/54 | 1.15 (0.67, 1.99) | 1.15 (0.66, 2.00) | |||
| 57–77 | 61/58 | 1.27 (0.74, 2.17) | 1.24 (0.72, 2.15) | |||
| 77–96 | 38/25 | 1.59 (0.83, 3.03) | 1.49 (0.76, 2.92) | |||
| 96–370 | 26/23 | 1.06 (0.53, 2.11) | 1.02 (0.50, 2.07) | |||
| Linear estimate per IQR | 225/220 | 0.99 (0.83, 1.17) | 0.96 (0.81, 1.15) | |||
| 3–5 | 30/50 | 1.00 | 1.00 | |||
| 5–7 | 35/42 | 1.23 (0.64, 2.35) | 1.19 (0.61, 2.30) | |||
| 7–10 | 42/32 | 1.56 (0.82, 2.96) | 1.53 (0.80, 2.91) | |||
| 10–15 | 27/21 | 1.64 (0.79, 3.41) | 1.76 (0.84, 3.67) | |||
| 15–39 | 21/11 | 2.60 (1.08, 6.27) | 2.52 (1.04, 6.09) | |||
| Linear estimate per IQR | 155/156 | 1.13 (0.94, 1.36) | 1.13 (0.94, 1.36) | |||
| 6–25 | 47/67 | 1.00 | 1.00 | |||
| 25–33 | 53/52 | 1.33 (0.78, 2.28) | 1.39 (0.81, 2.39) | |||
| 33–46 | 65/60 | 1.40 (0.84, 2.36) | 1.43 (0.85, 2.40) | |||
| 46–62 | 41/33 | 1.37 (0.75, 2.52) | 1.38 (0.75, 2.54) | |||
| 62–290 | 29/20 | 1.60 (0.79, 3.24) | 1.54 (0.76, 3.14) | |||
| Linear estimate per IQR | 235/232 | 1.03 (0.90, 1.18) | 1.01 (0.89, 1.16) | |||
| Compound/concentration | IRR (95% CI) | |||||
| Model 1 | Model 2 | |||||
| Oxychlordane | ||||||
| 8–19 | 30/52 | 1.00 | 1.00 | |||
| 19–25 | 38/46 | 1.31 (0.71, 2.43) | 1.33 (0.72, 2.46) | |||
| 25–33 | 46/39 | 1.87 (1.00, 3.49) | 1.86 (1.00, 3.47) | |||
| 33–41 | 34/18 | 2.81 (1.28, 6.14) | 2.69 (1.22, 5.96) | |||
| 41–354 | 21/16 | 1.95 (0.85, 4.46) | 1.92 (0.84, 4.41) | |||
| Linear estimate per IQR | 169/171 | 1.13 (0.92, 1.40) | 1.11 (0.89, 1.38) | |||
| Dieldrin | ||||||
| 6–13 | 33/32 | 1.00 | 1.00 | |||
| 13–20 | 21/52 | 0.38 (0.19, 0.76) | 0.36 (0.17, 0.73) | |||
| 20–29 | 35/37 | 0.95 (0.49, 1.85) | 0.91 (0.46, 1.79) | |||
| 29–41 | 22/12 | 2.05 (0.92, 4.54) | 1.94 (0.87, 4.34) | |||
| 41–350 | 18/11 | 1.42 (0.60, 3.36) | 1.27 (0.52, 3.12) | |||
| Linear estimate per IQR | 140/144 | 1.03 (0.94, 1.14) | 1.03 (0.94, 1.13) | |||
| Hexachlorobenzene | ||||||
| 9–37 | 47/56 | 1.00 | 1.00 | |||
| 37–53 | 50/51 | 1.08 (0.62, 1.88) | 1.07 (0.61, 1.87) | |||
| 53–72 | 45/56 | 0.84 (0.48, 1.49) | 0.77 (0.42, 1.43) | |||
| 72–98 | 37/33 | 1.15 (0.60, 2.18) | 1.07 (0.55, 2.09) | |||
| 98–360 | 25/17 | 1.25 (0.57, 2.72) | 1.16 (0.53, 2.58) | |||
| Linear estimate per IQR | 204/213 | 1.00 (0.82, 1.21) | 0.98 (0.80, 1.19) | |||
| ΣChlordanes | ||||||
| 9–37 | 55/59 | 1.00 | 1.00 | |||
| 37–58 | 51/68 | 0.77 (0.46, 1.30) | 0.75 (0.44, 1.27) | |||
| 58–83 | 64/53 | 1.18 (0.70, 1.99) | 1.10 (0.64, 1.91) | |||
| 83–108 | 35/35 | 0.84 (0.45, 1.55) | 0.80 (0.43, 1.50) | |||
| 108–439 | 30/17 | 1.41 (0.68, 2.94) | 1.32 (0.63, 2.79) | |||
| Linear estimate per IQR | 235/232 | 1.04 (0.86, 1.26) | 1.02 (0.84, 1.24) | |||
| ΣDDTs | ||||||
| 76–390 | 57/56 | 1.00 | 1.00 | |||
| 390–690 | 57/67 | 0.86 (0.51, 1.43) | 0.87 (0.52, 1.47) | |||
| 690–1,100 | 61/56 | 1.02 (0.61, 1.72) | 1.03 (0.61, 1.74) | |||
| 1,100–1,714 | 36/37 | 0.86 (0.48, 1.56) | 0.83 (0.46, 1.52) | |||
| 1,714–8,041 | 27/21 | 1.09 (0.56, 2.15) | 1.08 (0.55, 2.14) | |||
| Linear estimate per IQR | 238/237 | 1.03 (0.87, 1.23) | 1.03 (0.86, 1.23) | |||
IRRs for NHL and 95% CI in association with adipose tissue concentrations of PCBs.
| Compound/concentration | IRR (95% CI) | |||||
|---|---|---|---|---|---|---|
| Model 1 | Model 2 | |||||
| PCB-118 | ||||||
| 10–25 | 53/50 | 1.00 | 1.00 | |||
| 25–34 | 63/62 | 0.97 (0.57, 1.66) | 0.88 (0.50, 1.56) | |||
| 34–48 | 58/56 | 1.00 (0.59, 1.71) | 0.96 (0.55, 1.65) | |||
| 48–62 | 34/38 | 0.78 (0.42, 1.45) | 0.67 (0.34, 1.31) | |||
| 62–150 | 25/27 | 0.79 (0.40, 1.55) | 0.72 (0.36, 1.44) | |||
| Linear estimate per IQR | 233/233 | 0.92 (0.72, 1.17) | 0.88 (0.68, 1.14) | |||
| PCB-156 | ||||||
| 13–28 | 62/53 | 1.00 | 1.00 | |||
| 28–34 | 51/63 | 0.56 (0.33, 0.96) | 0.59 (0.34, 1.02) | |||
| 34–41 | 54/59 | 0.64 (0.38, 1.09) | 0.68 (0.40, 1.16) | |||
| 41–50 | 45/35 | 0.83 (0.46, 1.50) | 0.94 (0.51, 1.75) | |||
| 50–88 | 23/26 | 0.57 (0.28, 1.15) | 0.66 (0.31, 1.37) | |||
| Linear estimate per IQR | 235/236 | 0.95 (0.75, 1.20) | 1.01 (0.79, 1.29) | |||
| PCB-99 | ||||||
| 9–20 | 32/49 | 1.00 | 1.00 | |||
| 20–27 | 42/41 | 1.63 (0.88, 3.02) | 1.60 (0.85, 3.01) | |||
| 27–37 | 53/44 | 1.59 (0.87, 2.91) | 1.56 (0.84, 2.89) | |||
| 37–47 | 24/27 | 1.20 (0.58, 2.48) | 1.20 (0.58, 2.49) | |||
| 47–110 | 20/16 | 1.45 (0.61, 3.43) | 1.42 (0.59, 3.40) | |||
| Linear estimate per IQR | 171/177 | 1.10 (0.83, 1.44) | 1.09 (0.83, 1.43) | |||
| PCB-138 | ||||||
| 29–100 | 53/49 | 1.00 | 1.00 | |||
| 100–140 | 44/69 | 0.66 (0.38, 1.13) | 0.66 (0.38, 1.14) | |||
| 140–180 | 74/63 | 1.05 (0.63, 1.75) | 1.04 (0.62, 1.74) | |||
| 180–230 | 41/34 | 1.25 (0.67, 2.31) | 1.25 (0.67, 2.33) | |||
| 230–380 | 26/28 | 0.68 (0.34, 1.34) | 0.68 (0.34, 1.36) | |||
| Linear estimate per IQR | 238/243 | 0.99 (0.78, 1.25) | 0.99 (0.78, 1.26) | |||
| PCB-153 | ||||||
| 98–240 | 56/55 | 1.00 | 1.00 | |||
| 240–300 | 57/61 | 0.87 (0.52, 1.47) | 0.88 (0.52, 1.50) | |||
| 300–370 | 56/73 | 0.64 (0.38, 1.07) | 0.67 (0.40, 1.12) | |||
| 370–430 | 42/28 | 1.38 (0.75, 2.53) | 1.50 (0.81, 2.78) | |||
| 430–730 | 28/27 | 0.79 (0.39, 1.57) | 0.85 (0.42, 1.73) | |||
| Linear estimate per IQR | 239/244 | 0.94 (0.75, 1.19) | 0.97 (0.77, 1.23) | |||
| PCB-170 | ||||||
| 37–87 | 57/61 | 1.00 | 1.00 | |||
| 87–100 | 47/41 | 1.09 (0.63, 1.89) | 1.19 (0.68, 2.09) | |||
| 100–130 | 69/78 | 0.79 (0.48, 1.30) | 0.93 (0.54, 1.59) | |||
| 130–150 | 42/32 | 1.16 (0.64, 2.08) | 1.46 (0.75, 2.83) | |||
| 150–230 | 23/31 | 0.64 (0.32, 1.29) | 0.80 (0.38, 1.69) | |||
| Linear estimate per IQR | 238/243 | 0.89 (0.68, 1.18) | 0.98 (0.72, 1.33) | |||
| Compound/concentration | IRR (95% CI) | |||||
| Model 1 | Model 2 | |||||
| PCB-180 | ||||||
| 71–170 | 53/60 | 1.00 | 1.00 | |||
| 170–200 | 55/52 | 0.94 (0.56, 1.67) | 1.03 (0.60, 1.77) | |||
| 200–240 | 61/54 | 1.04 (0.62, 1.83) | 1.19 (0.69, 2.05) | |||
| 240–290 | 49/48 | 0.98 (0.50, 1.59) | 1.09 (0.59, 2.01) | |||
| 290–480 | 21/31 | 0.54 (0.27, 1.08) | 0.69 (0.32, 1.46) | |||
| Linear estimate per IQR | 239/245 | 0.90 (0.75, 1.08) | 0.99 (0.77, 1.27) | |||
| PCB-183 | ||||||
| 6–19 | 59/53 | 1.00 | 1.00 | |||
| 19–24 | 35/54 | 0.59 (0.34, 1.05) | 0.58 (0.32, 1.03) | |||
| 24–31 | 69/60 | 0.92 (0.55, 1.53) | 0.91 (0.54, 1.51) | |||
| 31–39 | 40/34 | 1.03 (0.56, 1.90) | 1.03 (0.56, 1.90) | |||
| 39–65 | 23/26 | 0.66 (0.33, 1.31) | 0.68 (0.34, 1.37) | |||
| Linear estimate per IQR | 226/227 | 0.87 (0.70, 1.08) | 0.88 (0.70, 1.10) | |||
| PCB-187 | ||||||
| 17–46 | 61/58 | 1.00 | 1.00 | |||
| 46–56 | 49/62 | 0.68 (0.40, 1.15) | 0.69 (0.40, 1.17) | |||
| 56–68 | 62/60 | 0.90 (0.54, 1.51) | 0.97 (0.57, 1.64) | |||
| 68–84 | 44/33 | 1.12 (0.60, 2.07) | 1.30 (0.68, 2.47) | |||
| 84–140 | 22/27 | 0.62 (0.30, 1.27) | 0.69 (0.33, 1.44) | |||
| Linear estimate per IQR | 238/240 | 0.88 (0.71, 1.11) | 0.92 (0.73, 1.15) | |||
| PCB-201 | ||||||
| 6–15 | 43/47 | 1.00 | 1.00 | |||
| 15–19 | 62/61 | 0.91 (0.52, 1.59) | 0.98 (0.56, 1.73) | |||
| 19–23 | 58/47 | 1.10 (0.62, 1.97) | 1.20 (0.66, 2.21) | |||
| 23–28 | 36/44 | 0.69 (0.37, 1.29) | 0.82 (0.41, 1.67) | |||
| 28–45 | 25/28 | 0.73 (0.34, 1.56) | 0.88 (0.38, 2.03) | |||
| Linear estimate per IQR | 224/227 | 0.85 (0.64, 1.13) | 0.93 (0.68, 1.28) | |||
| ΣPCB | ||||||
| 150–770 | 62/59 | 1.00 | 1.00 | |||
| 770–939 | 55/66 | 0.74 (0.45, 1.24) | 0.74 (0.44, 1.24) | |||
| 939–1,143 | 57/62 | 0.78 (0.47, 1.30) | 0.81 (0.48, 1.35) | |||
| 1,143–1,351 | 42/32 | 1.08 (0.59, 1.95) | 1.15 (0.63, 2.11) | |||
| 1,351–2,157 | 23/26 | 0.65 (0.32, 1.33) | 0.71 (0.34, 1.45) | |||
| Linear estimate per IQR | 239/245 | 0.95 (0.76, 1.19) | 0.99 (0.79, 1.25) | |||
| ΣPCBimmune | ||||||
| 150–530 | 60/58 | 1.00 | 1.00 | |||
| 530–650 | 55/63 | 0.77 (0.46, 1.30) | 0.79 (0.47, 1.34) | |||
| 650–790 | 59/65 | 0.77 (0.47, 1.29) | 0.82 (0.49, 1.38) | |||
| 790–930 | 42/32 | 1.15 (0.64, 2.09) | 1.29 (0.70, 2.38) | |||
| 930–1,490 | 23/27 | 0.62 (0.31, 1.26) | 0.68 (0.33, 1.41) | |||
| Linear estimate per IQR | 239/245 | 0.95 (0.76, 1.18) | 0.99 (0.78, 1.24) | |||
IRRs for NHL and 95% CI in association with adipose concentrations of p,p´-DDT, cis-nonachlor, and oxychlordane within strata of sex.
| Compound/concentration | IRR (95% CI) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Men | Women | Men | Women | |||||||
| 6–15 | 8/16 | 21/21 | 1.00 | 1.00 | ||||||
| 15–22 | 16/13 | 16/19 | 1.90 (0.60, 6.02) | 0.77 (0.31, 1.89) | ||||||
| 22–36 | 20/11 | 15/27 | 3.36 (1.06, 10.64) | 0.48 (0.20, 1.17) | ||||||
| 36–49 | 10/7 | 13/12 | 2.05 (0.53, 7.87) | 0.88 (0.31, 2.47) | ||||||
| 49–460 | 9/7 | 9/4 | 2.30 (0.60, 8.77) | 1.69 (0.47, 6.08) | ||||||
| Linear estimate per IQR | 63/54 | 74/83 | 1.50 (1.14, 1.98) | 1.15 (0.72, 1.86) | 0.35 | |||||
| 3–5 | 7/14 | 23/31 | 1.00 | 1.00 | ||||||
| 5–7 | 10/21 | 25/21 | 1.02 (0.30, 3.47) | 1.37 (0.60, 3.12) | ||||||
| 7–10 | 19/20 | 23/17 | 2.00 (0.61, 6.51) | 1.41 (0.59, 3.34) | ||||||
| 10–15 | 17/11 | 10/10 | 3.00 (0.86, 10.51) | 1.24 (0.45, 3.44) | ||||||
| 15–39 | 19/8 | 2/3 | 4.42 (1.21, 16.09) | 0.67 (0.10, 4.46) | ||||||
| Linear estimate per IQR | 72/74 | 83/82 | 1.39 (1.00, 1.93) | 0.94 (0.73, 1.20) | 0.06 | |||||
| Oxychlordane | ||||||||||
| 8–19 | 14/24 | 16/28 | 1.00 | 1.00 | ||||||
| 19–25 | 17/23 | 21/23 | 1.29 (0.52, 3.22) | 1.44 (0.62, 3.37) | ||||||
| 25–33 | 18/15 | 28/24 | 2.05 (0.78, 5.35) | 1.74 (0.76, 3.97) | ||||||
| 33–41 | 13/3 | 21/15 | 6.15 (1.46, 25.93) | 1.81 (0.71, 4.66) | ||||||
| 41–354 | 12/6 | 9/10 | 3.45 (0.97, 12.20) | 1.18 (0.39, 3.52) | ||||||
| Linear estimate per IQR | 74/71 | 95/100 | 1.27 (0.90, 1.79) | 0.97 (0.73, 1.29) | 0.23 | |||||